Transdermal treatment for malignant melanoma by aptamer-modified tetrahedral framework nucleic acid delivery of vemurafenib  

作　　者：Dexuan Xiao Tianyu Chen Tianxu Zhang Sirong Shi Mei Zhang Xin Qin Yunkun Liu Longjiang Li Yunfeng Lin 

机构地区：[1]State Key Laboratory of Oral Diseases,National Clinical Research Center for Oral Diseases,West China Hospital of Stomatology,Sichuan University,Chengdu 610041,China [2]Sichuan Provincial Engineering Research Center of Oral Biomaterials,Chengdu 610041,China [3]Department of Head and Neck Oncology,National Clinical Research Center for Oral Diseases,West China Hospital of Stomatology,Sichuan University,Chengdu 610041,China

出　　处：《Chinese Chemical Letters》2024年第4期260-267,共8页中国化学快报（英文版）

基　　金：supported by National Key R&D Program of China (No.2019YFA0110600);National Natural Science Foundation of China (No.81970916);Sichuan Science and Technology Program(No.2022NSFSC0002);Sichuan Province Youth Science and Technology Innovation Team (No.2022JDTD0021);Research and Develop Program;West China Hospital of Stomatology Sichuan University (No.RD03202302)。

摘　　要：Melanoma is one of the most malignant skin tumors, whose high invasion is generally associated with BRAF gene mutation. Although new chemotherapeutic drugs, such as vemurafenib, have been developed to inhibit the growth of melanoma, these drugs are usually administered intravenously or orally, resulting in toxic side effects on major tissues and organs. Tetrahedral framework nucleic acids(tFNAs) are a novel type of DNA nanostructures with excellent biocompatibility and versatility which have been proven to penetrate through skin barrier with ease. In this study, we prepared t FNAs with vemurafenib and connected DNA aptamer AS1411 at the apex of t FNAs(AS1411-tFNAs/vemurafenib). On one hand, AS1411-tFNAs/vemurafenib could kill melanoma cells by blocking the mutated BRAF gene in vitro. Compared with free vemurafenib, AS1411-tFNAs/vemurafenib had no obvious toxicity to normal cells. On the other hand,AS1411-tFNAs could transfer vemurafenib to cross through the skin barrier and permeate into tumor tissues. In vivo, transdermal delivery of AS1411-t FNAs/vemurafenib could inhibit the growth of human A375melanoma, whose inhibiting effect was stronger than intravenous administration of vemurafenib. These results demonstrated the application prospects of tFNAs combined with chemotherapeutic drugs in skin tumors.

关 键 词：MELANOMA VEMURAFENIB DNA nanostructure Transdermal treatment Side effect 

分 类 号：R943[医药卫生—药剂学]